Quality assessment of phase I dose-finding cancer trials: Proposal of a checklist

Clinical Trials

Volumn 5, Issue 5, 2008, Pages 478-485

  Zohar, Sarah ^a   Qing, Lian ^a   Levy, Vincent ^a   Cheung, Ken ^b   Ivanova, Anastasia ^c   Chevret, Sylvie ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Department of Medicine   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; CHECKLIST; CLINICAL RESEARCH; CYTOTOXICITY; DECISION MAKING; HUMAN; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DESIGN; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH CARE SURVEYS; HUMANS; QUALITY ASSURANCE, HEALTH CARE;

EID: 59349096738     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774508096653     Document Type: Article

References (32)

1. Storer B. Phase I trials. In Redmond, T. C.a.C. (ed.), Biostatistics in clinical trials John Wiley and Sons, Chichester, 2001, pp. 337-342.
2. Emanuel EJ A phase I trial on the ethics of phase I trials. J Clin Oncol 1995; 13(5): 1049-51.
3. Agrawal M., Emanuel EJ Ethics of phase 1 oncology studies: Reexamining the arguments and data. Jama 2003; 290(8):1075-82.
4. Ratain MJ, Mick R., Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 1993; 85(20): 1637-43.
5. Korn EL, Arbuck SG, Pluda JM et al. Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 2001; 19(1): 265-72.
6. O'Quigley J., Pepe M., Fisher L. Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46(1): 33-48.
7. Eisenhauer EA, O'Dwyer PJ, Christian M., Humphrey JS Phase I clinical trial design in cancer drug development. J Clin Oncol 2000; 18(3): 684-92.
8. Zhou Y. Choice of designs and doses for early phase trials. Fundam Clin Pharmacol 2004; 18(3): 373-8.
9. Horstmann E., McCabe MS, Grochow L., Yamamoto S. et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352(9): 895-904.
10. Roberts Jr TG, Goulart BH, Squitieri L., Stallings SC et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. Jama 2004; 292(17): 2130-40.
11. Chang SM, Reynolds SL, Butowski N. et al. GNOSIS: Guidelines for neuro-oncology: Standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol 2005; 7(4): 425-34.
12. Camacho LH, Bacik J., Cheung A., Spriggs DR Presentation and subsequent publication rates of phase I oncology clinical trials. Cancer 2005; 104(7): 1497-504.
13. Jadad AR, Moore RA, Carroll D., Jenkinson C. et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary ? Control Clin Trials 1996; 17(1): 1-12.
14. Verhagen AP, de Vet HC, de Bie RA, Kessels AG et al. The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51(12): 1235-41.
15. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. Jama 2001; 285(4): 437-43.
16. Altman DG, Schulz KF, Moher D., Egger M. et al. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 2001; 134(8): 663-94.
17. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52(6): 377-84.
18. Sung L., Hayden J., Greenberg M. L. et al. Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. J Clin Epidemiol 2005; 58(3): 261-8.
19. Linstone HA and Turoff M. The Delphi Method: Techniques and Applications. Addison-Wesley, Electronic edition of the book published in 1975, Harold A. Linstone and Murray Turoff edition, 2002.
20. Chalmers TC, Smith Jr H., Blackburn B., Silverman B. et al. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981; 2(1): 31-49.
21. Moher D., Schulz KF, Altman DG The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357(9263): 1191-4.
22. Pubmed Central. www.pubmed.org, 2005.
23. R Development Core Team. A language and environnement for statistical computing. R foundation for statistical computing, Vienna, Austria. http://www.r-project.org, 2005.
24. Strevel EL, Chau NG, Pond GR, Murgo AJ et al. Improving the quality of abstract reporting for phase I cancer trials. Clin Cancer Res 2008; 14(6): 1782-7.
25. Lévy V., Zohar S., Porcher R., Chevret S. Alternate designs for conduct and analysis of phase I cancer trials. Blood 2001; 98(4): 1275-6.
26. O'Quigley J., Zohar S. Experimental designs for phase I and phase I/II dose-finding studies. Br J Cancer 2006.
27. Paoletti X., Baron B., Schoffski P., Fumoleau P. et al. Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study. Eur J Cancer 2006; 42(10): 1362-8.
28. Kang SH, Ahn C. The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design. Drug Information Journal 2001; 35(4): 1189-1200.
29. Lin Y., Shih WJ Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2001; 2(2): 203-15.
30. Reiner E., Paoletti X., O'Quigley J. Operating characteristics of the standard phase I clinical trial design. Computational Statistics and Data Analysis 1999; 30: 303-315.
31. Ivanova A. Escalation, group and A + B designs for dose-finding trials. Stat Med 2006; 25(21): 3668-78.
32. Durham SD, Flournoy N., Rosenberger WF A random walk rule for phase I clinical trials. Biometrics 1997; 53(2): 745-60.